Abbott Laboratories and Raven biotechnologies Establish Research Collaboration For Antibody Therapeutics

04-Feb-2004

Abbott Laboratories and Raven biotechnologies, inc. have announced a research collaboration to evaluate a panel of Raven's proprietary monoclonal antibodies (MAbs), and their corresponding targets, for therapeutic and diagnostic applications. Financial terms of the agreement were not disclosed.

"We are extremely pleased to partner with Abbott. Their capabilities and commitment to therapeutic antibodies for oncology greatly enhance the potential of moving Raven's therapeutics into the clinic," said Jennie P. Mather, Ph.D., Founder, President and CEO of Raven. "We view this collaboration as a strong endorsement of our unique approach of using cell- based discovery methods to identify novel cancer targets and to rapidly obtain biologically active antibody drugs."

"This collaboration with Raven underscores Abbott's strong commitment to immunotherapeutics and to finding potential new treatment options for cancer patients," said Stephen W. Fesik, Ph.D., Divisional Vice President, Cancer Research, Abbott Laboratories. "Abbott's leadership in monoclonal antibody research coupled with Raven's discovery capabilities will help us bring effective new treatments to patients."

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous